Degos disease is a very rare condition in which small blood vessels become damaged and blocked. That injury can show up first on the skin as small, round spots that develop a pale, “porcelain-like” center with a red rim. In some people, the illness stays limited to the skin. In others, it can involve organs such as the intestines or the brain and become much more serious.
Because Degos disease is uncommon, it is often unfamiliar even to experienced clinicians, and there is no single test that confirms it in every case. Care usually focuses on careful evaluation, early detection of organ involvement, and tailored treatment plans. This article explains what Degos disease is, why it may happen, who may be at risk, what symptoms to watch for, how diagnosis is made, and what treatment and daily management typically involve.
Table of Contents
- What is Degos disease and what happens in the body?
- What causes Degos disease and who gets it?
- Early symptoms and serious complications to watch
- How doctors diagnose Degos disease
- Treatments: what helps and what is uncertain
- Living with Degos disease: monitoring, prevention, and when to seek care
What is Degos disease and what happens in the body?
Degos disease is also called atrophic papulosis or malignant atrophic papulosis. You may also see the name Köhlmeier–Degos disease. The key idea is the same: the smallest blood vessels in the skin (and sometimes in internal organs) can become injured and clogged. When a tiny vessel closes off, the tissue it feeds loses oxygen and nutrients, creating a small “island” of damage. On the skin, that damage forms a distinctive lesion: a round or oval bump that later develops a central white, scar-like depression with a thin red rim.
Clinicians often describe two broad patterns:
- Skin-limited (benign cutaneous) Degos disease: lesions are confined to the skin, sometimes for many years.
- Systemic (malignant) Degos disease: in addition to skin lesions, blood vessel injury can affect the gastrointestinal tract, the nervous system, or other organs.
It is important to know that the skin pattern alone does not perfectly predict the future. Some people remain skin-limited. Others develop systemic disease months or years after the first skin findings. That uncertainty is why follow-up and symptom tracking matter.
At the tissue level, biopsies commonly show changes consistent with reduced blood flow: a wedge-shaped area of injury in the skin and signs of vessel narrowing or clotting. Researchers have proposed several overlapping drivers, including abnormal clotting tendencies, immune system activation, and injury to the lining of blood vessels (the endothelium). In many patients, more than one process may be contributing at the same time.
A practical way to think about Degos disease is this: it behaves less like a typical rash and more like a vascular problem that happens to be visible on the skin. The skin is often the earliest “window” into what is happening in the body, which is why dermatology evaluation is frequently the first step toward diagnosis and monitoring.
What causes Degos disease and who gets it?
No single cause has been proven, and many cases appear sporadic (no family history). Most experts view Degos disease as a syndrome with several possible pathways that converge on the same final problem: small-vessel blockage and tissue injury. Current thinking often focuses on three interacting themes.
1) Blood vessel lining injury
The inner lining of blood vessels helps control clotting, inflammation, and blood flow. If that lining is damaged, the vessel can narrow, become “sticky,” and clot more easily. In Degos disease, some findings suggest the endothelium may be under abnormal immune attack or stress, leading to repeated micro-injuries.
2) Immune system overactivation
Some patients show patterns suggesting an overactive immune signaling response, including pathways linked to type I interferons (immune messenger proteins). This does not mean Degos disease is a straightforward autoimmune illness, but it supports the idea that immune-driven inflammation can contribute to vessel closure in at least a subset of people.
3) Abnormal clot formation in tiny vessels
Because the damage is “thrombo-occlusive” (clot-and-blockage), clinicians often evaluate for clotting risk factors. Some individuals with Degos disease have co-existing conditions that can increase clotting risk (for example, certain autoimmune connective tissue diseases). In other cases, no clear clotting trigger is found.
Risk factors and associated patterns
Degos disease can occur at different ages, but many reported cases begin in young to middle adulthood. Reported risk patterns include:
- No clear trigger: many people have no preceding infection, medication change, or illness that explains onset.
- Possible association with autoimmune connective tissue diseases: in some cases, Degos-like lesions occur alongside disorders such as lupus or related conditions.
- Rare familial clustering: a small number of families have been described, suggesting genetics may play a role for certain people, even though most cases are not inherited.
Because the condition is rare, “risk factor” data are limited and can be biased toward more severe reported cases. Still, if you or a loved one has new porcelain-centered papules plus unexplained abdominal pain, neurologic symptoms, or signs of systemic inflammation, clinicians usually treat that combination as a reason to evaluate urgently.
Early symptoms and serious complications to watch
Degos disease often announces itself on the skin first, and those skin findings can be deceptively calm—small spots that do not itch much and may not hurt. Paying attention to the pattern and to new symptoms elsewhere in the body is crucial, because systemic involvement is where risk rises.
Skin symptoms
Typical lesions are:
- Small (often a few millimeters), round or oval papules on the trunk and limbs
- A white, atrophic (scar-like) center that can look porcelain or chalky
- A red rim, sometimes with fine visible blood vessels
- Lesions that appear in “crops” over time, so new spots can continue to develop
Some people notice mild tenderness, burning, or no sensation at all. Lesions usually spare the palms and soles; the face may be less involved, though patterns vary.
Gastrointestinal symptoms
The intestines are among the most commonly affected internal organs in systemic disease. Symptoms can be vague at first and then escalate quickly. Watch for:
- Persistent or worsening abdominal pain
- Nausea, vomiting, bloating, or unexplained diarrhea
- Blood in stool or black/tarry stool
- Fever, severe tenderness, or a rigid abdomen (possible emergency)
A major feared complication is bowel infarction or perforation, where a damaged segment of bowel breaks down. This is a surgical emergency.
Nervous system symptoms
When blood vessels in the brain or spinal cord are involved, symptoms may include:
- New severe headaches, confusion, or marked fatigue
- Weakness, numbness, trouble speaking, facial droop, imbalance
- Seizures or vision changes
These symptoms can resemble stroke or inflammation of brain coverings and should be treated as urgent.
Other possible organ involvement
Less commonly, Degos disease can affect the eyes, heart lining, lung lining, or kidneys. Warning signs can include chest pain with breathing, shortness of breath, new swelling, or unusual vision loss.
A useful rule: skin-only lesions plus stable health may be monitored carefully, but skin lesions plus new abdominal or neurologic symptoms should prompt immediate medical evaluation.
How doctors diagnose Degos disease
Diagnosis is usually a step-by-step process that combines clinical recognition, biopsy findings, and a search for organ involvement. Because Degos disease is rare and can mimic other disorders, clinicians often aim for both accuracy and speed—especially if systemic symptoms are present.
1) Clinical exam and history
A dermatologist or experienced clinician looks for the characteristic lesion pattern and asks about:
- Timeline: when lesions started and whether they appear in crops
- Symptoms outside the skin: abdominal pain, headaches, neurologic changes
- Past medical history: autoimmune disease, clotting events, new medications
- Family history: rare but potentially relevant
Photos over time can help show evolution of lesions, which supports diagnosis.
2) Skin biopsy
A biopsy is often central. Pathologists may see features consistent with reduced blood flow and vessel blockage, such as:
- A wedge-shaped zone of skin injury extending downward
- Changes in small vessels suggesting occlusion or narrowing
- Overlying epidermal thinning and scarring in later lesions
Because early lesions can look different from older lesions under the microscope, clinicians sometimes biopsy a newer lesion and, if needed, a more developed one.
3) Tests to evaluate systemic involvement
If there are symptoms suggesting internal disease, evaluation may include:
- Blood work: complete blood count, inflammatory markers, clotting studies, and autoimmune screening when appropriate
- Imaging: CT or MRI based on symptoms (for example, abdominal CT for pain; brain MRI for neurologic changes)
- Endoscopy or laparoscopy decisions: standard endoscopy may miss early bowel involvement because much of the disease affects deeper vessels. In selected high-concern cases, some teams consider diagnostic laparoscopy to inspect the bowel surface directly.
- Consults: gastroenterology, neurology, rheumatology, and sometimes hematology
4) Ruling out look-alikes
Conditions that can resemble Degos disease include small-vessel vasculitis, antiphospholipid syndrome, livedoid vasculopathy, certain connective tissue diseases, and other causes of skin infarction or scarring papules. The goal is to avoid missing a more common condition with a proven, time-sensitive treatment while also not dismissing Degos disease when the lesion pattern is classic.
Diagnosis is best viewed as a combination of pattern recognition plus targeted testing, repeated over time if symptoms evolve.
Treatments: what helps and what is uncertain
There is no universally proven treatment for Degos disease, and evidence is limited because the condition is rare. Care is typically individualized based on whether disease is skin-limited or systemic, which organs are involved, and how active the process appears.
Skin-limited disease
When lesions are confined to the skin and there are no systemic symptoms, clinicians often focus on:
- Close monitoring: regular skin exams and symptom review
- Antiplatelet therapy (sometimes): medications that reduce platelet clumping may be considered in selected patients
- Addressing overlapping risk factors: treating smoking, uncontrolled blood pressure, or other vascular risks is reasonable even if not proven to change Degos outcomes
Because some people remain skin-limited for years, the most important “treatment” may be structured follow-up that catches systemic change early.
Systemic disease
When there is gastrointestinal or neurologic involvement, management often becomes urgent and multi-specialty. Approaches that have been used include:
- Complement inhibition (eculizumab): used in some reported cases to target immune-related vessel injury pathways; responses vary, and it may not prevent progression in every patient.
- Prostacyclin pathway therapy (treprostinil): used in some cases to support blood vessel function and reduce clotting tendency; sometimes combined with complement-targeted therapy.
- Anticoagulation and antiplatelets: often tried, especially when clotting tendency is suspected, though benefit is inconsistent across reports.
- Immunosuppressive medicines: steroids or other immunosuppressants have generally shown mixed or disappointing results in many reports, but may be considered when there is strong evidence of an overlapping autoimmune driver.
Surgery and supportive care
For bowel perforation, obstruction, or severe bleeding, surgical intervention can be lifesaving. Supportive care matters as well:
- Pain control and nutrition support when GI disease limits intake
- Infection prevention and rapid treatment if perforation or sepsis occurs
- Rehabilitation for neurologic deficits
What to expect from treatment conversations
Because evidence is limited, shared decision-making is central. A good care plan usually clarifies:
- Whether disease appears skin-limited or systemic today
- What “red flag” symptoms require immediate escalation
- Which therapy is being used, what success would look like, and how response will be measured
- How risks will be managed, including infection risk with immune-targeting medicines
If you are offered a therapy with limited data, it is reasonable to ask what is known, what is uncertain, and how the team will monitor both benefit and harm.
Living with Degos disease: monitoring, prevention, and when to seek care
Living with Degos disease often means living with uncertainty—especially early on, when it is not yet clear whether disease will remain skin-limited. A strong daily plan focuses on monitoring, symptom awareness, and reducing avoidable risks.
Monitoring that is practical and meaningful
Many clinicians recommend a structured follow-up schedule, especially in the first years after diagnosis. Useful elements include:
- Symptom tracking: a simple weekly log of abdominal pain, bowel changes, headaches, vision issues, or neurologic symptoms
- Photo documentation: monthly photos of representative lesions to track new crops or changes
- Periodic labs (when advised): especially if inflammatory markers were elevated or systemic therapy is used
- Targeted imaging: not routinely for everyone, but promptly when symptoms suggest organ involvement
If you are on immune-targeting treatment, monitoring also includes infection screening, vaccine planning, and clear instructions about fevers.
Prevention and risk reduction
There is no proven way to prevent Degos disease progression, but you can reduce strain on the vascular system and avoid complications:
- Do not smoke or vape nicotine products.
- Keep blood pressure, blood sugar, and cholesterol in healthy ranges.
- Stay hydrated, especially during illness or travel.
- Move regularly during long trips to reduce clot risk.
- Discuss estrogen-containing hormones with your clinician if you have clotting risk factors.
If you take antiplatelet or anticoagulant medicines, learn the signs of bleeding and how to handle missed doses safely.
When to seek urgent care
Seek emergency evaluation if any of the following occur:
- Severe or worsening abdominal pain, vomiting, fever, or a hard/tender abdomen
- Blood in stool or black/tarry stool
- Sudden weakness, numbness, speech trouble, severe headache, confusion, or seizures
- New chest pain with breathing, severe shortness of breath, or fainting
Building the right care team
Degos disease often benefits from coordinated care. Many people do best with a dermatologist plus a primary coordinating specialist (often rheumatology or internal medicine), with gastroenterology and neurology involved as needed. Because cases are rare, it can also help to be evaluated at a center experienced with complex vascular or inflammatory disorders.
The day-to-day goal is not to “think about Degos disease constantly,” but to have a plan that makes escalation fast when it truly matters.
References
- Clinical and laboratory prognosticators of atrophic papulosis (Degos disease): a systematic review – PubMed 2021 (Systematic Review)
- Gastrointestinal Kohlmeier-Degos disease: a narrative review – PubMed 2022 (Narrative Review)
- Atrophic papulosis (Köhlmeier-Degos disease) in children and adolescents-A cross-sectional study and literature review – PubMed 2023 (Review)
- Malignant atrophic papulosis treated with eculizumab and hirudin: a fatal case report and literature review – PMC 2024 (Case Report and Literature Review)
Disclaimer
This article is for educational purposes and does not replace medical advice, diagnosis, or treatment from a qualified clinician. Degos disease can be serious and may require urgent evaluation, especially if you develop abdominal pain, bleeding, or neurologic symptoms. If you think you may be experiencing an emergency, seek immediate medical care or call your local emergency number. Treatment decisions should be made with your healthcare team, based on your symptoms, test results, and overall health.
If you found this article helpful, please share it on Facebook, X (formerly Twitter), or any platform you prefer, and follow us on social media. Your support through sharing helps our team keep producing reliable, patient-focused health content.
